Why Japan is a global destination for regenerative medicine
Japan is emerging as a go-to hub for regenerative medicine, combining an ageing patient population with established, decade-long regulatory pathways,…
Featured s
Five considerations for adopting AI in clinical study build workflows
AI can accelerate study-build foundations, but only when teams combine targeted automation with standards, traceability and control.
All Articles
Why Japan is a global destination for regenerative medicine
Japan is emerging as a go-to hub for regenerative medicine, combining an ageing patient population with established, decade-long regulatory pathways,…
Five considerations for adopting AI in clinical study build workflows
AI can accelerate study-build foundations, but only when teams combine targeted automation with standards, traceability and control.
AAIC26: Alzheimer’s disease heterogeneity calls for a rethink
While progress has been made to influence the treatment landscape of Alzheimer’s disease, gaps to widespread therapeutic availability and imaging…
Novartis Q2 profits recover as revenue mantle passes to newer medicines
Novartis continues to navigate a decisive period as newer portfolio assets start to offset patent pressures.
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory
BMS enhances its AI computing power as big pharma race to stay competitive within the shifting global landscape.
EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168
C-CAR168 is aimed at depleting both autoreactive B cells and antibody-producing plasma cells.
Halozyme and Incyte sign licence agreement for INCA033989 formulations
The companies aim to enable simplified dosing and delivery methods for patients receiving treatment for MPNs.
What Ojemda’s JCA reveals about new era of clinical HTA in Europe
An analysis of GlobalData’s Drug Pricing (POLI) & HTA database shows no HTA outcome for Ojemda in the wake of…
Novartis and Takeda drugs gain rare blood cancer routine use on NHS
The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Completion of the deal is anticipated towards the end of 2026.